{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:32:08Z","timestamp":1791145928923,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1898,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1093\/annonc\/mdu038","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T01:53:43Z","timestamp":1395453223000},"page":"1700-1709","source":"Crossref","is-referenced-by-count":52,"title":["New agents for prostate cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"N.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu038_bb0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu038_bb0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu038_bb0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu038_bb0025","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu038_bb0030","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu038_bb0035","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu038_bb0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu038_bb0045","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","article-title":"Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer","volume":"11","author":"Titus","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0050","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0055","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdu038_bb0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mce.2008.08.013","article-title":"Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol","volume":"295","author":"Dillard","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1093\/annonc\/mdu038_bb0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601127","article-title":"Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer","volume":"89","author":"Edwards","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu038_bb0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0075","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2003.11.102","article-title":"Androgen receptor mutations in androgen-independent prostate cancer: cancer and Leukemia Group B Study 9663","volume":"21","author":"Taplin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0080","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-08-3605","article-title":"Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy","volume":"69","author":"Steinkamp","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0085","doi-asserted-by":"crossref","first-page":"e00499","DOI":"10.7554\/eLife.00499","article-title":"Overcoming mutation-based resistance to antiandrogens with rational drug design","volume":"2","author":"Balbas","year":"2013","journal-title":"Elife"},{"key":"10.1093\/annonc\/mdu038_bb0090","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdu038_bb0095","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdu038_bb0100","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdu038_bb0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdu038_bb0110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrurol.2010.134","article-title":"Therapeutic targeting of the prostate cancer microenvironment","volume":"7","author":"Karlou","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"suppl 5","key":"10.1093\/annonc\/mdu038_bb0115","article-title":"Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I\/II study","volume":"30","author":"Agus","year":"2012","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1093\/annonc\/mdu038_bb0120","article-title":"Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC)","author":"Hussain","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0125","unstructured":"Press release: http:\/\/investor.millennium.com\/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1841278&highlight 25 July 2013 (8 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu038_bb0130","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.5_suppl.198","article-title":"VT-464: a novel, selective inhibitor of P450c17(CYP17)-17, 20 lyase for castration-refractory prostate cancer (CRPC)","volume":"30","author":"Eisner","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0135","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0140","article-title":"A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer","volume":"30","author":"Rathkopf","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0145","doi-asserted-by":"crossref","unstructured":"Rathkopf DE, Antonarakis ES, Shore ND et al. ARN-509 in men with metastatic castration-resistant prostate cancer. In ESMO Congress, Vienna, Austria, September 2012. Available at: http:\/\/oncologypro.esmo.org\/ (Abstract 964 TIP).","DOI":"10.1016\/S0923-7534(20)33527-4"},{"key":"10.1093\/annonc\/mdu038_bb0150","doi-asserted-by":"crossref","unstructured":"Smith MR, Antonarakis ES, Ryan CJ et al. ARN-509 in men with high-risk nonmetastatic castration reistant prostate cancer. In ESMO Congress, Vienna, Austria, September 2012. Available at: http:\/\/oncologypro.esmo.org\/ (Abstract 920P).","DOI":"10.1200\/jco.2013.31.6_suppl.7"},{"key":"10.1093\/annonc\/mdu038_bb0155","series-title":"European Cancer Congress 2013, Amsterdam","article-title":"An open-label, phase I\/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)","author":"Fizazi","year":"2013"},{"key":"10.1093\/annonc\/mdu038_bb0160","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1158\/1535-7163.MCT-12-1174","article-title":"AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo","volume":"12","author":"Loddick","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0165","article-title":"A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC)","volume":"31","author":"Omlin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0170","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1172\/JCI66398","article-title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J Clin Invest"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0175","article-title":"Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC)","volume":"30","author":"Montgomery","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0180","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1158\/0008-5472.CAN-07-6154","article-title":"Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer","volume":"68","author":"Mehra","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0185","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.onc.1210640","article-title":"Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer","volume":"27","author":"Attard","year":"2008","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdu038_bb0195","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5004","article-title":"ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): results from the COU-AA-302 study in chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC)","volume":"31","author":"Attard","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0200","article-title":"A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel","volume":"31","author":"Chi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0205","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","article-title":"Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial","volume":"31","author":"Ryan","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0210","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0215","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu038_bb0220","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0225","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0230","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdu038_bb0235","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdu038_bb0240","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-04-0073","article-title":"External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing","volume":"64","author":"Chakraborty","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0245","series-title":"European Cancer Congress 2013, September\u20131 October 2013, Amsterdam","author":"Gerritsen","year":"2013"},{"key":"10.1093\/annonc\/mdu038_bb0250","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrclinonc.2011.72","article-title":"Immunotherapy for the treatment of prostate cancer","volume":"8","author":"Di Lorenzo","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0255","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1158\/1078-0432.CCR-05-0826","article-title":"Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer","volume":"11","author":"Morris","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0260","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO.2007.15.0532","article-title":"Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer","volume":"26","author":"Galsky","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0265","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","article-title":"Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer","volume":"22","author":"Milowsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0270","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1093\/annonc\/mdu038_bb0275","first-page":"284s","article-title":"Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC)","volume":"26","author":"Tagawa","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1093\/annonc\/mdu038_bb0280","article-title":"Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC)","volume":"28","author":"Tagawa","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0285","article-title":"A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)","volume":"31","author":"Danila","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0290","article-title":"Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane","volume":"31","author":"Petrylak","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0295","doi-asserted-by":"crossref","first-page":"833","DOI":"10.5483\/BMBRep.2008.41.12.833","article-title":"The hepatocyte growth factor\/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis","volume":"41","author":"You","year":"2008","journal-title":"BMB Rep"},{"key":"10.1093\/annonc\/mdu038_bb0300","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/1471-2407-10-556","article-title":"Efficacy of c-Met inhibitor for advanced prostate cancer","volume":"10","author":"Tu","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdu038_bb0305","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0310","author":"Scher","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0315","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5073","article-title":"Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET\/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib","author":"Fox","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0320","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.26.8771","article-title":"Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Chi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0325","doi-asserted-by":"crossref","unstructured":"Chi K, Yu E, Ellard S et al. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with metastatic castration resistant prostate cancer. In ESMO Congress, Vienna, Austria, September 2012. Abstract 900PD.","DOI":"10.1016\/S0923-7534(20)33525-0"},{"key":"10.1093\/annonc\/mdu038_bb0330","series-title":"NCT01681433: OGX-427 in metastatic castrate-resistant prostate cancer with prostate-specific antigen progression while receiving abiraterone","year":"2013"},{"key":"10.1093\/annonc\/mdu038_bb0335","author":"Heath","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0340","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","article-title":"Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer","volume":"29","author":"Pili","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0345","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5062","article-title":"A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC)","author":"Pinski","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0350","unstructured":"http:\/\/www.nih.gov\/news\/health\/dec2013\/nci-05.htm (8 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu038_bb0355","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mds119","article-title":"Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?","volume":"23","author":"Mezynski","year":"2012","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0360","article-title":"Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: sequencing might matter","volume":"31","author":"Angelergues","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1093\/annonc\/mdu038_bb0365","article-title":"Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer","volume":"31","author":"Schnadig","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0370","unstructured":"Sonpavde G, Bhor M, Hennessy D, et al. Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer. In ECCO\/ESMO Congress (Abstr P412). Amsterdam, The Netherlands 2013. Available at: http:\/\/oncologypro.esmo.org\/."},{"key":"10.1093\/annonc\/mdu038_bb0375","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/annonc\/mdr380","article-title":"Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy","volume":"23","author":"de Bono","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0380","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu038_bb0385","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu038_bb0390","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu038_bb0395","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.1093\/annonc\/mdu038_bb0400","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419350872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419350872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/9\/1700\/19446184\/mdu038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:35:55Z","timestamp":1648668955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419350872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":79,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0923753419350872"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu038","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}